Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The Massachusetts-based cancer stem cell company has struck two deals in as many days in an effort to move compounds into the clinic for various types of cancers and multiple targets.